TSE:RVX Resverlogix (RVX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free RVX Stock Alerts C$0.06 -0.01 (-8.33%) (As of 05:18 PM ET) Add Compare Share Share Today's RangeC$0.06▼C$0.0650-Day RangeC$0.06▼C$0.0752-Week RangeC$0.05▼C$0.15Volume7,200 shsAverage Volume36,842 shsMarket CapitalizationC$14.97 millionP/E RatioN/ADividend Yield7.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Resverlogix alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Resverlogix Stock (TSE:RVX)Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.Read More RVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVX Stock News HeadlinesFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsJanuary 11, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 4, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)December 19, 2023 | investing.comResverlogix Corp. (RVX) Earnings Dates & ReportsNovember 18, 2023 | morningstar.comResverlogix Corp RVXCFNovember 1, 2023 | morningstar.comResverlogix Corp RVXOctober 18, 2023 | theglobeandmail.comResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 4, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finance.yahoo.comResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophySeptember 26, 2023 | finance.yahoo.comAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAugust 29, 2023 | finance.yahoo.comResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesAugust 24, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp up on Wednesday (RVX)August 14, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Monday (RVX)July 12, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)June 29, 2023 | finance.yahoo.comResverlogix Announces Warrant Repricing and One-Year ExtensionJune 20, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 20, 2023 | finance.yahoo.comResverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 12, 2023 | finance.yahoo.comResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease PatientsJune 7, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - RVX.WT.AJune 6, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)May 25, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)May 18, 2023 | finance.yahoo.comCBOE RUSSELL 2000 VOLATILITY IN (^RVX)May 2, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp down on Monday (RVX)April 29, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Friday (RVX)April 28, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants flat on Thursday (RVX-WT-A)See More Headlines Receive RVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:RVX CUSIPN/A CIKN/A Webwww.resverlogix.com Phone+1-403-2549252FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-12,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-37.10% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow132.50 Book ValueC($0.26) per share Price / Book-0.21Miscellaneous Outstanding Shares272,170,000Free FloatN/AMarket CapC$14.97 million OptionableNot Optionable Beta0.78 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & SecretaryMr. Aaron Bradley Cann C.A.CPA, CBV, Chief Financial OfficerDr. Ewelina Kulikowski Ph.D.Chief Scientific OfficerDr. Michael Sweeney M.D. (Age 63)Senior Vice President of Clinical Development Comp: $511.56kSarah ZapotichnyDirector of Investor Relations & Corporate CommunicationsKey CompetitorsSirona BiochemCVE:SBMReunion NeuroscienceTSE:REUNNeptune Wellness SolutionsTSE:NEPTAntibe TherapeuticsTSE:ATEKane BiotechCVE:KNEView All Competitors RVX Stock Analysis - Frequently Asked Questions How have RVX shares performed in 2024? Resverlogix's stock was trading at C$0.07 at the beginning of 2024. Since then, RVX stock has decreased by 21.4% and is now trading at C$0.06. View the best growth stocks for 2024 here. When is Resverlogix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RVX earnings forecast. How were Resverlogix's earnings last quarter? Resverlogix Corp. (TSE:RVX) released its earnings results on Monday, April, 1st. The biotechnology company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of Resverlogix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Endocyte (ECYT), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX) and Royalty Pharma (RPRX). How do I buy shares of Resverlogix? Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:RVX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
